MiR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages 476-481

  Ji, Yun ^a   Wrzesinski, Claudia ^a   Yu, Zhiya ^a   Hu, Jinhui ^a   Gautam, Sanjivan ^a   Hawk, Nga V ^a   Telford, William G ^a   Palmer, Douglas C ^a   Franco, Zulmarie ^a   Sukumar, Madhusudhanan ^a   Roychoudhuri, Rahul ^a   Clever, David ^a   Klebanoff, Christopher A ^a   Surh, Charles D ^b   Waldmann, Thomas A ^a   Restifo, Nicholas P ^a   Gattinoni, Luca ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Institute for Basic Science   (South Korea)

Author keywords

Adoptive immunotherapy; Homeostatic cytokines; Lymphodepletion; MicroRNA 155

Indexed keywords

CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 7; MICRORNA 155; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; PROTEIN KINASE B; STAT5 PROTEIN; STAT5A PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; MELANOCYTE PROTEIN PMEL 17; MICRORNA; MIRN155 MICRORNA, MOUSE; STAT5A PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENETIC TRANSFECTION; HOST; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VITILIGO; WESTERN BLOTTING; WHOLE BODY RADIATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; METABOLISM; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; GP100 MELANOMA ANTIGEN; HEK293 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84920983137     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422916112     Document Type: Article

References (40)

1. Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39(1):49-60.
2. Gattinoni L, Powell DJ, Jr, Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 6(5):383-393.
3. Antony PA, et al. (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174(5):2591-2601.
4. Yao X, et al. (2012) Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24):5688-5696.
5. Paulos CM, et al. (2007) Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117(8): 2197-2204.
6. Gattinoni L, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907-912.
7. Wrzesinski C, et al. (2007) Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest 117(2):492-501.
8. Wrzesinski C, et al. (2010) Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33(1):1-7.
9. Rosenberg SA, et al. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550-4557.
10. Dudley ME, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346-2357.
11. Dudley ME, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233-5239.
12. Muranski P, et al. (2006) Increased intensity lymphodepletion and adoptive immunotherapy- how far can we go? Nat Clin Pract Oncol 3(12):668-681.
13. Acquavella N, et al. (2008) Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 31(6):569-576.
14. Bartel DP (2009) MicroRNAs: Target recognition and regulatory functions. Cell 136(2): 215-233.
15. Vigorito E, Kohlhaas S, Lu D, Leyland R (2013) miR-155: An ancient regulator of the immune system. Immunol Rev 253(1):146-157.
16. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D (2010) Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10(2):111-122.
17. Vigorito E, et al. (2007) microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27(6):847-859.
18. Rodriguez A, et al. (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316(5824):608-611.
19. O'Connell RM, et al. (2010) MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33(4):607-619.
20. Lu LF, et al. (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30(1):80-91.
21. Dudda JC, et al. (2013) MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38(4):742-753.
22. Gracias DT, et al. (2013) The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol 14(6):593-602.
23. Huffaker TB, et al. (2012) Epistasis between microRNAs 155 and 146a during T cellmediated antitumor immunity. Cell Reports 2(6):1697-1709.
24. Overwijk WW, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198(4):569-580.
25. Costinean S, et al. (2006) Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103(18): 7024-7029.
26. Burns WR, Zheng Z, Rosenberg SA, Morgan RA (2009) Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114(14):2888-2899.
27. Liao W, Lin JX, LeonardWJ (2011) IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 23(5):598-604.
28. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D (2009) Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA 106(17):7113-7118.
29. Wiede F, La Gruta NL, Tiganis T (2014) PTPN2 attenuates T-cell lymphopenia-induced proliferation. Nat Commun 5:3073.
30. Kleppe M, et al. (2010) Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 42(6):530-535.
31. Kopp KL, et al. (2013) STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 12(12):1939-1947.
32. Cho HI, Reyes-Vargas E, Delgado JC, Celis E (2012) A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res 72(8):1986-1995.
33. Pegram HJ, et al. (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18):4133-4141.
34. Kerkar SP, et al. (2010) Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 70(17):6725-6734.
35. Hand TW, et al. (2010) Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci USA 107(38):16601-16606.
36. Gattinoni L, et al. (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15(7):808-813.
37. Ji Y, et al. (2011) Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol 12(12):1230-1237.
38. Kalos M, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73.
39. Di Stasi A, et al. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673-1683.
40. Zhang L, et al. (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19(4):751-759.